title: Maxillary sinus augmentation procedures through equine-derived biomaterial or calvaria autologous bone: immunohistochemical evaluation of OPG/RANKL in humans.
abstract: Autologous bone is considered the gold standard for bone regeneration, even if different heterologous bone substitutes have been proposed to overcome the limits related to its use. The aim of this study was to analyze and to compare the molecular events switched on by autologous or heterologous bone graft insertion, focusing on TGFβ1 expression and OPG/RANKL ratio, to analyze resorption process, and estimating graft vascularization, new bone tissue deposition and its mineralization, through VEGF, BSP and SPARC expression evaluation, respectively. Patients needing pre-prosthetic rehabilitation of the posterior maxilla were treated using an equine-derived biomaterial (Group 1) or calvaria autologous bone (Group 2), according to the morphology of the bone defect. Bone graft integration was evaluated on bone samples obtained from the treated areas at the moment of dental implant insertion, by morphological and immunohistochemical analyses for TGFβ1, OPG, RANKL, VEGF, BSP, and SPARC expression. Morphological analysis shows the presence of biomaterial residual granules in Group 1, in parallel to a good integration between graft and host tissue. Moderate TGFβ1 expression is seen in both Group 1 and Group 2. OPG/RANKL ratio appear higher in Group 1; VEGF expression appears very strong in Group 1 and strong in Group 2, while BSP and SPARC expression results weak in Group 1 and moderate in Group 2. Results reveal the good integration between both types of graft and the host tissue, even though autologous graft seems to produce a faster regenerative process, as evidenced by the different expression of the investigated molecules. According to these observations, the clinical use of heterologous particulate equine-derived biomaterial may ensure long-term predictability of implant-prosthetic rehabilitation, comparable to that obtained with autologous bone graft.
authors.affiliation: Department of Medical, Oral and Biotechnological Sciences, University "G. d' Annunzio" Chieti-Pescara, Chieti, Scalo, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Tetè
authors.forename: R
authors.initials: R
authors.lastname: Vinci
authors.forename: V L
authors.initials: VL
authors.lastname: Zizzari
authors.forename: S
authors.initials: S
authors.lastname: Zara
authors.forename: V
authors.initials: V
authors.lastname: La Scala
authors.forename: A
authors.initials: A
authors.lastname: Cataldi
authors.forename: E
authors.initials: E
authors.lastname: Gherlone
authors.forename: A
authors.initials: A
authors.lastname: Piattelli
mesh_terms: D000818:Animals; D018786:Bone Substitutes / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D005786:Gene Expression Regulation; D006736:Horses; D006801:Humans; D008297:Male; D008437:Maxilla / Q000002:abnormalities / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D053244:Osteoprotegerin / Q000096:biosynthesis*; D053245:RANK Ligand / Q000096:biosynthesis*; D012886:Skull / Q000737:chemistry*; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous
chemical_list: D018786:Bone Substitutes; D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D053773:Transforming Growth Factor beta1
references.citation: J Bone Miner Res. 2001 Oct;16(10):1787-94
references.pmid: 11585342
references.citation: Eur J Histochem. 2011;55(3):e31
references.pmid: 22073377
references.citation: Acta Histochem. 2012 Dec;114(8):805-12
references.pmid: 22564496
references.citation: Clin Implant Dent Relat Res. 2001;3(2):87-96
references.pmid: 11472655
references.citation: Arthritis Rheum. 2003 Mar;48(3):824-8
references.pmid: 12632438
references.citation: J Bone Miner Res. 2010 Dec;25(12):2669-79
references.pmid: 20812227
references.citation: Endocrinology. 1996 Jun;137(6):2347-54
references.pmid: 8641185
references.citation: J Oral Implantol. 2006;32(3):122-31
references.pmid: 16836176
references.citation: J Cell Biochem. 2003 Apr 1;88(5):873-84
references.pmid: 12616527
references.citation: Clin Oral Implants Res. 2009 Jan;20(1):17-23
references.pmid: 19126103
references.citation: Nat Med. 1999 Jun;5(6):623-8
references.pmid: 10371499
references.citation: Int J Oral Maxillofac Implants. 2009 Jan-Feb;24(1):131-6
references.pmid: 19344036
references.citation: Clin Oral Implants Res. 2010 Sep;21(9):961-70
references.pmid: 20497443
references.citation: Bone. 2006 Jun;38(6):749-57
references.pmid: 16412713
references.citation: J Craniofac Surg. 2010 Jul;21(4):1147-52
references.pmid: 20613590
references.citation: BMC Med. 2011 May 31;9:66
references.pmid: 21627784
references.citation: Bone. 2008 Feb;42(2):250-9
references.pmid: 18063436
references.citation: Clin Interv Aging. 2010 Nov 19;5:345-54
references.pmid: 21228900
references.citation: Curr Stem Cell Res Ther. 2008 Dec;3(4):254-64
references.pmid: 19075755
references.citation: Endocrinology. 2001 Dec;142(12):5050-5
references.pmid: 11713196
references.citation: Int J Oral Maxillofac Implants. 1998;13 Suppl:11-45
references.pmid: 9715571
references.citation: Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1105-16
references.pmid: 20074475
references.citation: Int J Oral Maxillofac Implants. 2007 Jul-Aug;22(4):527-32
references.pmid: 17929512
references.citation: Clin Exp Rheumatol. 2005 Mar-Apr;23(2):185-92
references.pmid: 15895888
references.citation: J Exp Med. 2008 May 12;205(5):1145-53
references.pmid: 18458111
references.citation: J Craniofac Surg. 2011 Sep;22(5):1702-7
references.pmid: 21959416
references.citation: Clin Implant Dent Relat Res. 2009 Jun;11(2):90-100
references.pmid: 18783426
references.citation: J Bone Joint Surg Am. 2002 Jun;84(6):1032-44
references.pmid: 12063342